• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
Reply
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier
Yazar(lar) :
DirkJan Hijnen , Carla Bruijnzeel-Koomen , Edward Knol
Yıl :
2010
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.jaci.2010.04.034
ISSN: 0091-6749
Sayı: 1
Cilt: 126
Sayfa: 184
Sınıflandırma :
2
Atopic dermatitis: A tale of two distinct pathomechanisms that make you itch
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
European Journal of Immunology
Yazar(lar) :
Edward F. Knol , DirkJan Hijnen
Konu :
Immunology, Immunology and Allergy
Yıl :
2016
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Atopic dermatitis (AD) or eczema is the most common chronic inflammatory skin disease. It is a multifactorial disease with local and systemic immune changes. Current therapies focus on restoring the local skin barrier or inhibiting immune responses. In this issue of the European Journal of Immunology, Sehra et al. [Eur. J. Immunol. 2016. 46:2609–2613] describe a mouse model with T‐cell‐specific expression of constitutively active Stat6 in Flaky tail mice, which have mutations in the Flg and Tmem79 genes. The authors describe that it is the combination of changes in the skin barrier proteins filaggrin and Tmem79, together with Th2 cytokine signaling in the constitutively active Stat6 transgene, that drives the immune‐pathomechanism in AD. These results are consistent with human studies where it is demonstrated that diminished filaggrin expression in skin is a predisposing factor for AD, but is neither required nor sufficient for disease indicating that additional factors are required for disease development. The current mouse model by Sehra et al. could be instrumental in evaluation new therapeutic strategies for AD.
DOI : 10.1002/eji.201646708
ISSN: 0014-2980
Sayı: 11
Cilt: 46
Sayfa: 2512-2515
3
Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier
Yazar(lar) :
Judith L. Thijs , Athula Herath , Marjolein S. de Bruin-Weller , DirkJan Hijnen
Yıl :
2017
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.jaci.2016.08.023
ISSN: 0091-6749
Sayı: 3
Cilt: 139
Sayfa: 1065
Sınıflandırma :
4
New Developments in Biomarkers for Atopic Dermatitis
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak 1:
Directory of Open Access Journals (DOAJ)
Kaynak 2:
MDPI
Dergi:
Journal of Clinical Medicine
Yazar(lar) :
Judith L. Thijs , Wouter van Seggelen , Carla Bruijnzeel-Koomen , Marjolein de Bruin-Weller , DirkJan Hijnen
Yıl :
2015
DirkJan Hijnen
Piri Tam Metin Bulucu
Kaydet Alıntıla
The application of biomarkers in medicine is evolving. Biomarkers do not only give us a better understanding of pathogenesis, but also increase treatment efficacy and safety, further enabling more precise clinical care. This paper focuses on the current use of biomarkers in atopic dermatitis, new developments and future perspectives. Biomarkers can be used for many different purposes, including the objective determination of disease severity, confirmation of clinical diagnosis, and to predict response to treatment. In atopic dermatitis, many biomarkers have been investigated as a marker for disease severity. Currently serum thymus and activation-regulated chemokine (TARC) is the superior biomarker for assessing disease severity. However, we have recently shown that the use of a panel of serum biomarkers is more suitable for assessing disease severity than an individual biomarker. In this overview, we will discuss alternative sources for biomarkers, such as saliva and capillary blood, which can increase the user friendliness of biomarkers in atopic dermatitis (AD). Both methods offer simple, non-invasive and cost effective alternatives to venous blood. This provides great translational and clinical potential. Biomarkers will play an increasingly important role in AD research and personalized medicine. The use of biomarkers will enhance the efficacy of AD treatment by facilitating the individualization of therapy targeting the patients’ specific biological signature and also by providing tools for predicting and monitoring of therapeutic response.
DOI : 10.3390/jcm4030479
Anahtar Kelimeler : atopic dermatitis, eczema, biomarkers, disease severity, stratification, dried blood spots, saliva
ISSN: 2077-0383
Cilt: 4
Sayı: 3
Sayfa: 479 - 487
Sınıflandırma :
5
Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of the American Academy of Dermatology
Yayıncı:
Elsevier
Yazar(lar) :
Janneke Landheer , Marjolein de Bruin-Weller , Chantal Boonacker , DirkJan Hijnen , Carla Bruijnzeel-Koomen , Heike Röckmann
Yıl :
2014
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Background Serum thymus and activation-regulated chemokine (sTARC) levels reflect disease severity of atopic dermatitis (AD) in small study populations. It remains unclear whether sTARC is a reliable outcome measurement for AD severity in heterogeneous AD populations in daily practice. Objective We sought to assess the utility of sTARC as a biomarker for monitoring AD severity in adults in daily practice. Methods sTARC, clinical skin score (Six Area, Six Sign AD [SASSAD]), and body surface area measurements were collected from all adult patients with AD visiting our clinic between March 2009 and March 2012, at first visit or exacerbation (baseline). In addition, data from short-term and long-term follow-up visits were collected. Results At baseline sTARC levels ranged widely (n = 320; minimum-maximum: 3-50,400 pg/mL) and sTARC and SASSAD or body surface area correlated moderately. In the majority of patients, sTARC and SASSAD or body surface area changed congruently during follow-up. Limitations Data were collected retrospectively. Conclusion sTARC may represent a suitable biomarker for monitoring of AD severity in daily practice.
DOI : 10.1016/j.jaad.2014.07.031
Anahtar Kelimeler : atopic dermatitis, body surface area, disease severity, follow-up, serum thymus and activation-regulated chemokine, Six Area, Six Sign Atopic Dermatitis, AD atopic dermatitis, atopic dermatitis, BSA body surface area, body surface area, SASSAD Six Area, Six Sign Atopic Dermatitis, Six Area, Six Sign Atopic Dermatitis, SCORAD SCORing Atopic Dermatitis, SCORing Atopic Dermatitis, sTARC serum thymus and activation-regulated chemokine, serum thymus and activation-regulated chemokine
ISSN: 0190-9622
Sayı: 6
Cilt: 71
Sayfa: 1160-1166
Sınıflandırma :
6
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier BV
Yazar(lar) :
Yael Renert-Yuval , Jacob P. Thyssen , Robert Bissonnette , Thomas Bieber , Kenji Kabashima , DirkJan Hijnen , Emma Guttman-Yassky
Yıl :
2021
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations. Because therapeutic response may vary on the basis of heterogeneous clinical and molecular phenotypes, a shift toward precision medicine approaches may improve AD management. Herein, we will consider biomarkers as potential instruments in the toolbox of precision medicine in AD and will review the process of biomarker development and validation, the opinion of AD experts on the use of biomarkers, types of biomarkers, encompassing biomarkers that may improve AD diagnosis, biomarkers reflecting disease severity, and those potentially predicting AD development, concomitant atopic diseases, or therapeutic response, and current practice of biomarkers in AD. We found that chemokine C-C motif ligand 17/thymus and activation-regulated chemokine, a chemoattractant of TH2 cells, has currently the greatest evidence for robust correlation with AD clinical severity, at both baseline and during therapy, by using the recommendations, assessment, development, and evaluation approach. Although the potential of biomarkers in AD is yet to be fully elucidated, due to the complexity of the disease, a comprehensive approach taking into account both clinical and reliable, AD-specific biomarker evaluations would further facilitate AD research and improve patient management.
DOI : 10.1016/j.jaci.2021.01.013
Anahtar Kelimeler : Atopic dermatitis, biomarker, International Eczema Council, CCL17/TARC, IgE, eosinophils, CCL22/MDC, CCL26/eotaxin-3, CCL27/CTACK, CCL18/pulmonary and activation-regulated chemokine, IL-13, IL-22, AD Atopic dermatitis, Atopic dermatitis, CCL Chemokine C-C motif ligand, Chemokine C-C motif ligand, CTACK Cutaneous T-cellu2013attracting chemokine, Cutaneous T-cellu2013attracting chemokine, FDA Food and Drug Administration, Food and Drug Administration, FLG Filaggrin, Filaggrin, GRADE Grading of Recommendations, Assessment, Development, and Evaluation, Grading of Recommendations, Assessment, Development, and Evaluation, IEC International Eczema Council, International Eczema Council, MDC Macrophage-derived chemokine, Macrophage-derived chemokine, TARC Thymus and activation-regulated chemokine, Thymus and activation-regulated chemokine
ISSN: 0091-6749
Sayı: 4
Cilt: 147
Sayfa: 1174-1190.e1
7
Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell–attracting chemokine (CTACK) levels in allergic diseasesTARC and CTACK are disease-specific markers for atopic dermatitis
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier
Yazar(lar) :
DirkJan Hijnen , Marjolein de Bruin-Weller , Bert Oosting , Cristina Lebre , Esther de Jong , Carla Bruijnzeel-Koomen , Edward Knol
Yıl :
2004
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Background Tissue infiltration of CD4+ T cells plays an important role in the pathogenesis of allergic diseases. T-cell trafficking is mediated by specific chemokines and their receptors. Objective The purpose of this study was to investigate the participation of the chemokines thymus and activation-regulated chemokine (TARC) and cutaneous T cell–attracting chemokine (CTACK) in a large population of patients with allergic diseases. Methods Serum TARC and CTACK levels were measured in 455 patients with allergic disease. Patients were characterized as having atopic dermatitis (AD), allergic asthma, allergic rhinitis, or combinations or as healthy control subjects. Serum TARC and CTACK levels were correlated with disease activity in patients with AD. Furthermore, in 7 patients with AD, serum TARC and CTACK levels were studied after the start of systemic cyclosporin A treatment. Finally, TARC and CTACK localization was checked by immunohistochemistry in lesional skin biopsy specimens of patients with AD. Results Both TARC and CTACK serum levels in patients with AD were significantly higher than those in healthy control subjects and patients with allergic respiratory disease. Furthermore, serum TARC and CTACK levels significantly correlated with disease activity in patients with AD. Serum TARC levels paralleled clinical improvement in patients treated with cyclosporin A. Immunoreactive TARC was found in infiltrating cells and endothelial cells of the dermis but not in epidermal cells. Conclusions The serum TARC level is an objective parameter for disease severity specific for AD. Furthermore, it is a promising tool for treatment monitoring.
DOI : 10.1016/j.jaci.2003.12.007
Anahtar Kelimeler : Allergic disease, asthma, atopic dermatitis, rhinitis, TH2, chemokines, TARC, CTACK, cyclosporin A, AA Allergic asthma, Allergic asthma, AD Atopic dermatitis, Atopic dermatitis, AR Allergic rhinitis, Allergic rhinitis, CLA Cutaneous lymphocyte antigen, Cutaneous lymphocyte antigen, CsA Cyclosporin A, Cyclosporin A, CTACK Cutaneous T cellu2013attracting chemokine, Cutaneous T cellu2013attracting chemokine, HC Healthy control subject, Healthy control subject, LSS Leicester Severity Score, Leicester Severity Score, PGA Physician's Global Assessment, Physician's Global Assessment, TARC Thymus and activation-regulated chemokine, Thymus and activation-regulated chemokine
ISSN: 0091-6749
Sayı: 2
Cilt: 113
Sayfa: 334-340
Sınıflandırma :
8
SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Emerging Infectious Diseases
Yazar(lar) :
DirkJan Hijnen , Angelo Valerio Marzano , Kilian Eyerich , Corine GeurtsvanKessel , Ana Maria Giménez-Arnau , Pascal Joly , Christian Vestergaard , Michael Sticherling , Enno Schmidt
Yıl :
2020
DirkJan Hijnen
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
During a meeting in Munich, Germany, a presymptomatic attendee with severe acute respiratory syndrome coronavirus 2 infected at least 11 of 13 other participants. Although 5 participants had no or mild symptoms, 6 had typical coronavirus disease, without dyspnea. Our findings suggest hand shaking and face-to-face contact as possible modes of transmission.
DOI : 10.3201/eid2608.201235
Anahtar Kelimeler : COVID-19, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, viruses, respiratory infections, zoonoses
Cilt: 26
Sayı: 8
Sayfa: 1935 - 1937
Sınıflandırma :
9
EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with Cyclosporin A.
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
Allergy
Yazar(lar) :
Judith L Thijs , Julia Drylewicz , Carla A F M Bruijnzeel-Koomen , Barbara Giovannone , Edward F Knol , Marjolein S de Bruin-Weller , Stefan Nierkens , DirkJan Hijnen
Yıl :
2018
DirkJan Hijnen
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.1111/all.13651
Sınıflandırma :
10
Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Archives of Dermatological Research
Yazar(lar) :
Linde E. M. de Wijs , Sven van Egmond , Arjan C. A. Devillers , Tamar Nijsten , DirkJan Hijnen , Marjolein Lugtenberg
Konu :
Dermatology, General Medicine
Yıl :
2022
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
To optimally tailor atopic dermatitis (AD) care to patients’ needs, especially considering the many emerging therapeutic options, insight into patients’ needs and preferences regarding AD care is needed. To explore patients’ needs and preferences regarding AD care, a qualitative study consisting of three focus groups with a total of 20 adult AD patients was conducted. All sessions were transcribed verbatim and inductively analyzed using several phases of coding to create an overview of patients’ needs and preferences. AD patients emphasized the need for a patient-tailored approach in all identified aspects of AD care. With regard to consultations, patients stressed the need for a personal approach and increased recognition of the disease impact, which should mainly be determined by patients. With regard to the organization of AD care, the need for psychosocial and medical supportive care as well as quick access to health-care providers during disease flares was emphasized. Within the decision-making process, patients indicated that the provided information, the role of the patient and physician, whether or not treatment goals should be set, and decisive factors for indication and feasibility of novel therapies should be patient dependent. AD care should be patient tailored with increased attention for the psychosocial burden, as well as better access to health care during disease flares. To provide patient-tailored care, the personal situation, needs, and preferences of the patient should be taken into account in the therapeutic decision-making process, with respect for the autonomy of the patient.
DOI : 10.1007/s00403-021-02321-z
Anahtar Kelimeler : Atopic dermatitis, Atopic eczema, Therapy, Qualitative research, Patient-centered care
ISSN: 0340-3696 1432-069X
11
Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in nonlesional skin of patients with atopic dermatitis
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier
Yazar(lar) :
Janneke Landheer , Barbara Giovannone , Jeanine D. Mattson , Sandra Tjabringa , Carla A.F.M. Bruijnzeel-Koomen , Terrill McClanahan , Rene de Waal Malefyt , Edward Knol , DirkJan Hijnen
Yıl :
2013
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.jaci.2013.07.051
ISSN: 0091-6749
Sayı: 5
Cilt: 132
Sayfa: 1252-1254
Sınıflandırma :
12
Cyclosporin A reduces CD4+CD25+ regulatory T-cell numbers in patients with atopic dermatitis
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier
Yazar(lar) :
DirkJan Hijnen , Inge Haeck , Annemieke A. van Kraats , Evert Nijhuis , Marjolein S. de Bruin-Weller , Carla A.F.M. Bruijnzeel-Koomen , Edward F. Knol
Yıl :
2009
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.jaci.2009.07.056
ISSN: 0091-6749
Sayı: 4
Cilt: 124
Sayfa: 856-858
Sınıflandırma :
13
Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of the American Academy of Dermatology
Yayıncı:
Elsevier BV
Yazar(lar) :
Angela L. Bosma , Linde E.M. de Wijs , Michel H. Hof , Beau R. van Nieuwenhuizen , Louise A.A. Gerbens , Maritza A. Middelkamp-Hup , DirkJan Hijnen , Phyllis I. Spuls
Yıl :
2021
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.jaad.2021.02.072
ISSN: 0190-9622
Sayı: 3
Cilt: 85
Sayfa: e173-e174
Sınıflandırma :
14
Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of the American Academy of Dermatology
Yayıncı:
Elsevier
Yazar(lar) :
Angela L. Bosma , Linde E.M. de Wijs , Michel H. Hof , Beau R. van Nieuwenhuizen , Louise A.A. Gerbens , Maritza A. Middelkamp-Hup , DirkJan Hijnen , Phyllis I. Spuls
Yıl :
2020
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Background Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. Objective To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment. Methods An observational prospective cohort study was conducted of patients with atopic dermatitis starting dupilumab in routine clinical care. Results Of the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks, we found a change of −15.2 (SE, 1.7) for the Eczema Area and Severity Index, −16.9 (SE, 1.4) for the Patient-Oriented Eczema Measure, and −17.2 (SE, 1.6) for the Dermatology Life Quality Index. We found a trend for improvement over time for the Investigator Global Assessment and Numerical Rating Scale for pruritus. Severe (n = 79) including serious (n = 11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n = 46). Twenty-one patients adjusted the regular dosing schedule, and 14 patients discontinued treatment, mainly due to ineffectiveness (n = 7). Limitations Only adverse events of severe and serious nature were registered for feasibility reasons. Conclusion Daily practice dupilumab treatment of up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms, and quality of life.
DOI : 10.1016/j.jaad.2020.05.128
Anahtar Kelimeler : atopic dermatitis, atopic eczema, daily practice, dupilumab, effectiveness, registry, routine clinical care, safety, systemic immunomodulating treatment, AD atopic dermatitis, atopic dermatitis, AE adverse event, adverse event, DLQI Dermatology Life Quality Index, Dermatology Life Quality Index, EASI Eczema Area and Severity Index, Eczema Area and Severity Index, EMC Erasmus MC University Medical Center, Erasmus MC University Medical Center, IGA Investigator Global Assessment, Investigator Global Assessment, NRS Numerical Rating Scale, Numerical Rating Scale, POEM Patient-Oriented Eczema Measure, Patient-Oriented Eczema Measure, TREAT NL TREatment of ATopic eczema, the Netherlands, TREatment of ATopic eczema, the Netherlands, UMC University Medical Centers, University Medical Centers
ISSN: 0190-9622
Sayı: 5
Cilt: 83
Sayfa: 1375-1384
Sınıflandırma :
15
EASI p‐ EASI : Predicting disease severity in atopic dermatitis patients treated with cyclosporin A
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Allergy
Yazar(lar) :
Judith L. Thijs , Julia Drylewicz , Carla A. F. M. Bruijnzeelu2010Koomen , Barbara Giovannone , Edward F. Knol , Marjolein S. de Bruinu2010Weller , Stefan Nierkens , DirkJan Hijnen
Konu :
Immunology, Immunology and Allergy
Yıl :
2018
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1111/all.13651
ISSN: 0105-4538

16
EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Allergy
Yazar(lar) :
Daphne S. Bakker , Lieneke F. M. Ariens , Barbara Giovannone , DirkJan Hijnen , Eveline M. Delemarre , Edward Knol , Stefan Nierkens , Marjolein S. Bruinu2010Weller , Judith L. Thijs , Julia Drylewicz
Konu :
Immunology, Immunology and Allergy
Yıl :
2020
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1111/all.14492
ISSN: 0105-4538
Sayı: 12
Cilt: 75
Sayfa: 3287-3289
17
Signal Inhibitory Receptor on Leukocytes-1 is highly expressed on lung monocytes, but absent on mononuclear phagocytes in skin and colon
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Cellular Immunology
Yayıncı:
Elsevier
Yazar(lar) :
Helen J. von Richthofen , Doron Gollnast , Toni M.M. van Capel , Barbara Giovannone , Geertje H.A. Westerlaken , Lisanne Lutter , Bas Oldenburg , DirkJan Hijnen , Michiel van der Vlist , Esther C. de Jong , Linde Meyaard
Yıl :
2020
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Signal Inhibitory Receptor on Leukocytes-1 (SIRL-1) is expressed on human blood monocytes and granulocytes and inhibits myeloid effector functions. On monocytes, but not granulocytes, SIRL-1 expression is low or absent in individuals with the single nucleotide polymorphism (SNP) rs612529C. The expression of SIRL-1 in tissue and the influence of rs612529 hereon is currently unknown. Here, we used flow cytometry to determine SIRL-1 expression on immune cells in human blood and three barrier tissues; skin, colon and lung. SIRL-1 was expressed by virtually all neutrophils and eosinophils in these tissues. In contrast, SIRL-1 was not expressed by monocyte-derived cells in skin and colon, whereas it was highly expressed by lung classical monocytes. Lung monocytes from individuals with a rs612529C allele had decreased SIRL-1 expression, consistent with the genotype association in blood. Within the different monocyte subsets in blood and lung, SIRL-1 expression was highest in classical monocytes and lowest in nonclassical monocytes. SIRL-1 was not expressed by dendritic cells in blood and barrier tissues. Together, these results indicate that SIRL-1 is differentially expressed on phagocyte subsets in blood and barrier tissues, and that its expression on monocytes is genotype- and tissue-specific. Immune regulation of monocytes by SIRL-1 may be of particular importance in the lung.
DOI : 10.1016/j.cellimm.2020.104199
Anahtar Kelimeler : Inhibitory receptor, Immune checkpoint, Barrier tissue, Phagocyte, Mononuclear phagocyte, Granulocyte
ISSN: 0008-8749
Cilt: 357
Sayfa: 104199
Sınıflandırma :
18
Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Allergy
Yazar(lar) :
Judith L. Thijs , Renée Fiechter , Barbara Giovannone , Marjolein S. de Bruinu2010Weller , Edward F. Knol , Carla A. F. M. Bruijnzeelu2010Koomen , Julia Drylewicz , Stefan Nierkens , DirkJan Hijnen
Yıl :
2019
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1111/all.13839
ISSN: 0105-4538
Sayı: 11
Cilt: 74
Sayfa: 2240-2243
Sınıflandırma :
19
TSLP is differentially regulated by vitamin D3 and cytokines in human skin
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Immunity, Inflammation and Disease
Yazar(lar) :
Janneke Landheer , Barbara Giovannone , Svetlana Sadekova , Sandra Tjabringa , Claudia Hofstra , Koen Dechering , Carla Bruijnzeelu2010Koomen , Charlie Chang , Yu Ying , Rene de Waal Malefyt , DirkJan Hijnen , Edward Knol
Yıl :
2015
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1002/iid3.48
ISSN: 2050-4527
Sayı: 1
Cilt: 3
Sayfa: 32-43
20
PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation.
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
J. Clin. Invest.
Yazar(lar) :
Alessandra Petrelli , Gerdien Mijnheer , David P Hoytema van Konijnenburg , Maria M van der Wal , Barbara Giovannone , Enric Mocholi , Nadia Vazirpanah , Jasper C Broen , Dirkjan Hijnen , Bas Oldenburg , Paul J Coffer , Sebastian J Vastert , Berent J Prakken , Eric Spierings , Aridaman Pandit , Michal Mokry , Femke van Wijk
Yıl :
2018
Dirkjan Hijnen
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Chronic inflammatory diseases are characterized by recurrent inflammatory attacks in the tissues mediated by autoreactive T cells. Identity and functional programming of CD8+ T cells at the target site of inflammation still remain elusive. One key question is whether, in these antigen-rich environments, chronic stimulation leads to CD8+ T cell exhaustion comparable to what is observed in infectious disease contexts. In the synovial fluid (SF) of juvenile idiopathic arthritis (JIA) patients, a model of chronic inflammation, an overrepresentation of PD-1+CD8+ T cells was found. Gene expression profiling, gene set enrichment analysis, functional studies, and extracellular flux analysis identified PD-1+CD8+ T cells as metabolically active effectors, with no sign of exhaustion. Furthermore, PD-1+CD8+ T cells were enriched for a tissue-resident memory (Trm) cell transcriptional profile and demonstrated increased clonal expansion compared with the PD-1- counterpart, suggesting antigen-driven expansion of locally adapted cells. Interestingly, this subset was also found increased in target tissues in other human chronic inflammatory diseases. These data indicate that local chronic inflammation drives the induction and expansion of CD8+ T cells endowed with potential detrimental properties. Together, these findings lay the basis for investigation of PD-1-expressing CD8+ T cell targeting strategies in human chronic inflammatory diseases.
DOI : 10.1172/JCI96107
Anahtar Kelimeler : Immunology, T cells
Sınıflandırma :
21
Association between nasal and nasopharyngeal bacterial colonization in early life and eczema phenotypes
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Clinical & Experimental Allergy
Yazar(lar) :
Chen Hu , Liesbeth Duijts , Evelien R. Meel , Kirsten I. M. Looman , Jessica C. Kiefteu2010de Jong , Luba M. Pardo , DirkJan Hijnen , Suzanne G. M. A. Pasmans , Johan C. Jongste , Henriette A. Moll , Tamar Nijsten
Konu :
Immunology, Immunology and Allergy
Yıl :
2021
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1111/cea.13869
ISSN: 0954-7894

22
Serum biomarker profiles suggest that atopic dermatitis is a systemic disease
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier
Yazar(lar) :
Judith L. Thijs , Ian Strickland , Carla A.F.M. Bruijnzeel-Koomen , Stefan Nierkens , Barbara Giovannone , Edward F. Knol , Eszter Csomor , Bret R. Sellman , Tomas Mustelin , Matthew A. Sleeman , Marjolein S. de Bruin-Weller , Athula Herath , Julia Drylewicz , Richard D. May , DirkJan Hijnen
Yıl :
2018
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1016/j.jaci.2017.12.991
ISSN: 0091-6749
Sayı: 4
Cilt: 141
Sayfa: 1523-1526
Sınıflandırma :
23
Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Journal of Allergy and Clinical Immunology
Yayıncı:
Elsevier
Yazar(lar) :
Judith L. Thijs , Ian Strickland , Carla A.F.M. Bruijnzeel-Koomen , Stefan Nierkens , Barbara Giovannone , Eszter Csomor , Bret R. Sellman , Tomas Mustelin , Matthew A. Sleeman , Marjolein S. de Bruin-Weller , Athula Herath , Julia Drylewicz , Richard D. May , DirkJan Hijnen
Yıl :
2017
DirkJan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Background Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease with a diverse clinical presentation. However, it is unclear whether this diversity exists at a biological level. Objective We sought to test the hypothesis that AD is heterogeneous at the biological level of individual inflammatory mediators. Methods Sera from 193 adult patients with moderate-to-severe AD (six area, six sign atopic dermatitis [SASSAD] score: geometric mean, 22.3 [95% CI, 21.3-23.3] and 39.1 [95% CI, 37.5-40.9], respectively) and 30 healthy control subjects without AD were analyzed for 147 serum mediators, total IgE levels, and 130 allergen-specific IgE levels. Population heterogeneity was assessed by using principal component analysis, followed by unsupervised k-means cluster analysis of the principal components. Results Patients with AD showed pronounced evidence of inflammation compared with healthy control subjects. Principal component analysis of data on sera from patients with AD revealed the presence of 4 potential clusters. Fifty-seven principal components described approximately 90% of the variance. Unsupervised k-means cluster analysis of the 57 largest principal components delivered 4 distinct clusters of patients with AD. Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary and activation-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD14. Cluster 2 had low SASSAD scores with the lowest levels of IFN-α, tissue inhibitor of metalloproteinases 1, and vascular endothelial growth factor. Cluster 3 had high SASSAD scores with the lowest levels of IFN-β, IL-1, and epithelial cytokines. Cluster 4 had low SASSAD scores but the highest levels of the inflammatory markers IL-1, IL-4, IL-13, and thymic stromal lymphopoietin. Conclusion AD is a heterogeneous disease both clinically and biologically. Four distinct clusters of patients with AD have been identified that could represent endotypes with unique biological mechanisms. Elucidation of these endotypes warrants further investigation and will require future intervention trials with specific agents, such as biologics.
DOI : 10.1016/j.jaci.2017.03.023
Anahtar Kelimeler : Atopic dermatitis, unsupervised cluster analysis, disease heterogeneity, clusters, phenotypes, endotypes, personalized medicine, principal component analysis, AD Atopic dermatitis, Atopic dermatitis, BSA Body surface area, Body surface area, GRO-α Growth-regulated oncogene-alpha, Growth-regulated oncogene-alpha, ISAC Immuno-solid Phase Allergen Chip, Immuno-solid Phase Allergen Chip, PARC Pulmonary and activation-regulated chemokine, Pulmonary and activation-regulated chemokine, PCA Principal component analysis, Principal component analysis, SASSAD Six area, six sign atopic dermatitis, Six area, six sign atopic dermatitis, sCD14 Soluble CD14, Soluble CD14, TARC Thymus and activation-regulated chemokine, Thymus and activation-regulated chemokine, TIMP-1 Tissue inhibitor of metalloproteinases 1, Tissue inhibitor of metalloproteinases 1, TSLP Thymic stromal lymphopoietin, Thymic stromal lymphopoietin, VEGF Vascular endothelial growth factor, Vascular endothelial growth factor
ISSN: 0091-6749
Sayı: 3
Cilt: 140
Sayfa: 730-737
Sınıflandırma :
24
Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Arthritis & Rheumatology
Yazar(lar) :
Emmerik F. A. Leijten , Tessa S. van Kempen , Marianne Boes , Jocea M. R. Michels-van Amelsfort , Dirkjan Hijnen , Sarita A. Y. Hartgring , Joel A. G. van Roon , Mark H. Wenink , Timothy R. D. J. Radstake
Yıl :
2015
Dirkjan Hijnen
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1002/art.39261
ISSN: 2326-5191
Sayı: 10
Cilt: 67
Sayfa: 2673-2678

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

  Tüm Veritabanlarını Gör

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler